Combined treatment options for resectable common bile duct cancer patients
Open Access
- 20 September 2020
- journal article
- research article
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 25 (3) , 123-130
Abstract
Комбинированное лечение больных резектабельным раком общего желчного протокаKeywords
This publication has 20 references indexed in Scilit:
- Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 studyThe Lancet Oncology, 2019
- The effect of adjuvant chemotherapy in resectable cholangiocarcinoma: A meta-analysis and systematic reviewHepatobiliary & Pancreatic Diseases International, 2019
- Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III StudyJournal of Clinical Oncology, 2019
- Impact of adjuvant chemotherapy after pancreaticoduodenectomy for distal cholangiocarcinoma: a propensity score analysis from a French multicentric cohortLangenbeck's Archives of Surgery, 2018
- Improved Survival in Surgically Resected Distal Cholangiocarcinoma Treated with Adjuvant Therapy: a Propensity Score Matched AnalysisJournal of Gastrointestinal Surgery, 2018
- Multicentre study of the impact of factors that may affect long-term survival following pancreaticoduodenectomy for distal cholangiocarcinomaHPB, 2018
- Identification of Patients for Adjuvant Therapy After Resection of Carcinoma of the Extrahepatic Bile Ducts: A Propensity Score-Matched AnalysisAnnals of Surgical Oncology, 2017
- Long-Term Outcome of Distal Cholangiocarcinoma after Pancreaticoduodenectomy Followed by Adjuvant Chemoradiotherapy: A 15-Year Experience in a Single InstitutionCancer Research and Treatment, 2017
- Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinomaCancer Chemotherapy and Pharmacology, 2016
- Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trialBMC Cancer, 2015